Impact of Empagliflozin on Cardiovascular Outcomes and Renal Function in Patients with Obesity and Type 2 Diabetes: A Retrospective Cohort Study
Empagliflozin significantly improved cardiovascular and renal outcomes in Chinese populations with obesity and T2DM, with sustained benefits observed over 6 months. Elevated HbA1c, lower DBP, increased albuminuria, and reduced eGFR were associated with higher risks of adverse events during treatment period, highlighting the necessity of careful monitoring in high-risk patients.
Authors
- H. Gao (ORCID: https://orcid.org/0000-0002-9669-3088)
- Yuan‐Yu Lin (ORCID: https://orcid.org/0000-0002-3397-3218)
- Hongxia Ren (ORCID: https://orcid.org/0000-0003-2909-4365)
- Ye Guo (ORCID: https://orcid.org/0009-0003-8042-1840)
- Shuxian Song
Institutions
- Xi'an Medical University (CN)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1007/s13300-025-01753-4
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29